Terms: = Leukemia AND YWHAE, P62258, 7531, ENSG00000108953, 14-3-3 epsilon, FLJ45465, MDS, MDCR, KCIP-1, 14-3-3E AND Prognosis
1194 results:
1. [Research Progress on Prognostic Factors in Patients with Lower-Risk Myelodysplastic Syndrome--Review].
Liu JN; Chen BA; Cheng J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Oct; 32(5):1626-1630. PubMed ID: 39479859
[TBL] [Abstract] [Full Text] [Related]
2. RNA methylation sequencing shows different gene expression signatures for response to azacytidine therapy in high-grade myelodysplastic syndromes.
Gulei D; Moisoiu V; Kegyes D; Drula R; Iluta S; Tigu AB; Nistor M; Jitaru C; Bancos A; Rotariu P; Popovici C; Dima D; Tomai R; Rus I; Constantinescu C; Munteanu R; Cenariu D; Sezerman U; Zdrenghea M; Cermak J; Einsele H; Ghiaur G; Tomuleasa C
J Cell Mol Med; 2024 Sep; 28(18):e70078. PubMed ID: 39334509
[TBL] [Abstract] [Full Text] [Related]
3. [Long-term hypomethylating agents in patients with myelodysplastic syndromes: a multi-center retrospective study].
Liu XZ; Zhou SJ; Huang J; Zhao CF; Jiang LX; Zhang YD; Mei C; Ma LY; Zhou XP; Shao YP; Wu GQ; Xiao XB; Yao RX; Du XH; Hu TL; Qian SX; Li Y; Yan XF; Huang L; Wang ML; Fu JP; Shou LH; Jiang WH; Jin WM; Li LJ; Le J; Luo WJ; Zhang Y; Zhou XJ; Zhang H; Lang XH; Zhou M; Jin J; Jiang HF; Zhang J; Ouyang GF; Tong HY
Zhonghua Xue Ye Xue Za Zhi; 2024 Aug; 45(8):738-747. PubMed ID: 39307720
[No Abstract] [Full Text] [Related]
4. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses.
DiNardo CD; Verma D; Baran N; Bhagat TD; Skwarska A; Lodi A; Saxena K; Cai T; Su X; Guerra VA; Poigaialwar G; Kuruvilla VM; Konoplev S; Gordon-Mitchell S; Pradhan K; Aluri S; Hackman GL; Chaudhry S; Collins M; Sweeney SR; Busquets J; Rathore AS; Deng Q; Green MR; Grant S; Demo S; Choudhary GS; Sahu S; Agarwal B; Spodek M; Thiruthuvanathan V; Will B; Steidl U; Tippett GD; Burger J; Borthakur G; Jabbour E; Pemmaraju N; Kadia T; Kornblau S; Daver NG; Naqvi K; Short NJ; Garcia-Manero G; Tiziani S; Verma A; Konopleva M
Nat Cancer; 2024 Oct; 5(10):1515-1533. PubMed ID: 39300320
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic impact of DTA mutation and co-occurring mutations in patients with myelodysplastic syndrome.
Wang M; Chen P; Li D; Zhao M
Mol Biol Rep; 2024 Sep; 51(1):985. PubMed ID: 39278886
[TBL] [Abstract] [Full Text] [Related]
6. Modelling and drug targeting of a myeloid neoplasm with atypical 3q26/MECOM rearrangement using patient-specific iPSCs.
Nakamura M; Chonabayashi K; Narita M; Matsumura Y; Nishikawa M; Ochi Y; Nannya Y; Hishizawa M; Inoue D; Delwel R; Ogawa S; Takaori-Kondo A; Yoshida Y
Br J Haematol; 2024 Oct; 205(4):1430-1443. PubMed ID: 39187468
[TBL] [Abstract] [Full Text] [Related]
7. Variation characteristics and clinical significance of
Ma Q; Liu Y; Zhao H; Guo Y; Sun W; Hu R
Hematology; 2024 Dec; 29(1):2387878. PubMed ID: 39140716
[No Abstract] [Full Text] [Related]
8. Influence of genetic co-mutation on chemotherapeutic outcome in NPM1-mutated and FLT3-ITD wild-type AML patients.
Wu Q; Zhang Y; Yuan B; Huang Y; Jiang L; Liu F; Yan P; Cheng J; Long Z; Jiang X
Cancer Med; 2024 Aug; 13(15):e70102. PubMed ID: 39126219
[TBL] [Abstract] [Full Text] [Related]
9. Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1-mutated AML.
Smith E; Atenafu EG; Bankar A; Chan S; Davidson M; Gupta V; Minden MD; Richard-Carpentier G; Schimmer A; Schuh AC; Sibai H; Yee K; Maze D
Eur J Haematol; 2024 Nov; 113(5):716-726. PubMed ID: 39113600
[TBL] [Abstract] [Full Text] [Related]
10. Clinical features and prognosis of patients with myeloid neoplasms harboring t(7;11)(p15;p15) translocation: a single-center retrospective study.
Liu L; Zhao S; Wang L; Xu H; Chen Z; Tu J; Huang J; Jin J; Tong H
BMC Cancer; 2024 Aug; 24(1):955. PubMed ID: 39103751
[TBL] [Abstract] [Full Text] [Related]
11. Current challenges in conditioning regimens for mds transplantation.
Notarantonio AB; Robin M; D'Aveni M
Blood Rev; 2024 Sep; 67():101223. PubMed ID: 39089962
[TBL] [Abstract] [Full Text] [Related]
12. TRANSFORMATION OF MYELODYSPLASTIC SYNDROME INTO ACUTE MYELOBLASTIC leukemia (CLINICAL CASE).
Baidurin S; Bekenova F; Baitenova L; Darybaeva A; Kurmangalieva K
Georgian Med News; 2024 May; (350):98-102. PubMed ID: 39089279
[TBL] [Abstract] [Full Text] [Related]
13. Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion.
Montoro MJ; Palomo L; Haferlach C; Acha P; Chan O; Navarro V; Kubota Y; Schulz FI; Meggendorfer M; Briski R; Al Ali N; Xicoy B; López-Cadenas F; Bosch F; González T; Eder LN; Jerez A; Wang YH; Campagna A; Santini V; Bernal Del Castillo T; Such E; Tien HF; Diaz Varela N; Platzbecker U; Haase D; Díez-Campelo M; Della Porta M; Garcia-Manero G; Wiseman DH; Germing U; Maciejewski JP; Komrokji RS; Sole F; Haferlach T; Valcárcel D
Blood; 2024 Oct; 144(16):1722-1731. PubMed ID: 39074355
[TBL] [Abstract] [Full Text] [Related]
14. The roles of phosphorylation of signaling proteins in the prognosis of acute myeloid leukemia.
Márton A; Veres KB; Erdődi F; Udvardy M; Illés Á; Rejtő L
Pathol Oncol Res; 2024; 30():1611747. PubMed ID: 39035053
[TBL] [Abstract] [Full Text] [Related]
15. Computing cell state discriminates the aberrant hematopoiesis and activated microenvironment in Myelodysplastic syndrome (mds) through a single cell genomic study.
Guo X; Jin W; Wen Y; Wang Z; Ren X; Liu Z; Fu R; Cai Z; Li L
J Transl Med; 2024 Jul; 22(1):673. PubMed ID: 39033303
[TBL] [Abstract] [Full Text] [Related]
16. Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes.
Jann JC; Hergott CB; Winkler M; Liu Y; Braun B; Charles A; Copson KM; Barua S; Meggendorfer M; Nadarajah N; Shimony S; Winer ES; Wadleigh M; Stone RM; DeAngelo DJ; Garcia JS; Haferlach T; Lindsley RC; Luskin MR; Stahl M; Tothova Z
Leukemia; 2024 Sep; 38(9):1992-2002. PubMed ID: 39033241
[TBL] [Abstract] [Full Text] [Related]
17. [Clinical efficacy of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome-evolved acute myeloid leukemia].
Chen SL; Shi YY; Zhang LN; Gong M; Zhang XY; Zhao XL; Hao MZ; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):364-369. PubMed ID: 38951064
[No Abstract] [Full Text] [Related]
18. Fetal hemoglobin induction in azacytidine responders enlightens methylation patterns related to blast clearance in higher-risk mds and CMML.
Chatzilygeroudi T; Chondrou V; Boers R; Siamoglou S; Athanasopoulou K; Verigou E; Gribnau J; Alexis S; Labropoulou V; Kourakli A; Patrinos GP; Sgourou A; Symeonidis A
Clin Epigenetics; 2024 Jun; 16(1):79. PubMed ID: 38879530
[TBL] [Abstract] [Full Text] [Related]
19. High hyperdiploid karyotype with ≥ 49 chromosomes represents a heterogeneous subgroup of acute myeloid leukemia with differential TP53 mutation status and prognosis: a single-center study from China.
Zhang Z; Fu C; Sun Y; Liu Y; Wang Q; Yan W; Wu C; Wang Q; Zeng Z; Wen L; Shen H; Yao L; Liu D; Chen S; Pan J
Ann Hematol; 2024 Jul; 103(7):2337-2346. PubMed ID: 38849603
[TBL] [Abstract] [Full Text] [Related]
20. A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms.
Abdulbaki R; Pullarkat ST
Curr Oncol; 2024 Apr; 31(5):2353-2363. PubMed ID: 38785456
[TBL] [Abstract] [Full Text] [Related]
[Next]